论文部分内容阅读
目的观察普拉克索联合左旋多巴治疗帕金森病的临床疗效。方法选取2014年1月—2015年1月隆昌县人民医院收治的帕金森病患者100例,根据治疗方法分为对照组和观察组,每组50例。对照组患者单纯给予左旋多巴治疗,观察组患者给予普拉克索联合左旋多巴治疗。比较两组患者汉密尔顿抑郁量表(HAMD)和帕金森病统一评分量表(UPDRS)评分及不良反应发生率。结果观察组患者HAMD评分及UPDRSⅠ、Ⅱ、Ⅲ、Ⅳ型评分均低于对照组(P<0.05)。观察组患者不良反应发生率低于对照组(P<0.05)。结论普拉克索联合左旋多巴治疗帕金森病的临床疗效较好,安全性高。
Objective To observe the clinical efficacy of pramipexole combined with levodopa in the treatment of Parkinson’s disease. Methods 100 patients with Parkinson’s disease admitted from January 2014 to January 2015 in Longchang County People’s Hospital were divided into control group and observation group according to the treatment method, 50 cases in each group. Patients in the control group were treated with levodopa alone and patients in the observation group received pramipexole plus levodopa. Hamilton Depression Rating Scale (HAMD) and Parkinson’s Disease Uniform Rating Scale (UPDRS) scores and incidence of adverse reactions were compared between the two groups. Results The scores of HAMD and UPDRS Ⅰ, Ⅱ, Ⅲ and Ⅳ in observation group were lower than those in control group (P <0.05). The incidence of adverse reactions in observation group was lower than that in control group (P <0.05). Conclusions Pramipexole combined with levodopa in the treatment of Parkinson’s disease has good clinical efficacy and high safety.